Company & Sponsor Intelligence

Institute for Neurodegenerative Disorders

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials9

Recruiting0

Completed5

Countries1

Therapeutic footprint

alzheimersparkinsons

Indexed studies

NCT00287248Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
alzheimers · United StatesPHASE1

NCT00134784Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
parkinsons · PHASE2

NCT00273351Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
parkinsons · United StatesPHASE2

NCT00886951Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
alzheimers · United StatesPHASE1

NCT00605059Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
alzheimers · United StatesPHASE1

NCT01028209Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
alzheimers · United StatesPHASE1

NCT01217021Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
alzheimers · United StatesEARLY_PHASE1

NCT00870974A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
alzheimers · United StatesPHASE1

NCT00657813Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
alzheimers · United StatesPHASE1

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →